Medical Sciences Group/Intra-University Cooperative LaboratoriesIshii Laboratory (Division of Vaccine Science, IMS)

Newly established in January 2019, this laboratory aims to make vaccines a robust discipline; it became independent in 2010 and, after working at Osaka University and the Institute of Biomedical Research and Innovation, has consistently focused on elucidating the immune regulatory mechanisms of nucleic acids (DNA, RNA) in infectious diseases and other immune-related disorders and their physiological significance, as well as on nucleic acid The research activities include the development of vaccines, adjuvants and alternative immunotherapies using nucleic acids. Based on these research results, we aim to realise a 'Bench to Clinic' by making the most of our own clinical experience and clinical trial review experience. Specific research activities include,

(1) elucidate cell death, innate immune responses and antigen-specific responses induced by vaccines and adjuvants at the spatio-temporal and molecular level (Fig. 1).

(2) Comprehensive analysis at the biological to cellular level, as well as at the genetic and atomic (structural) level, to identify biomarkers of vaccine efficacy and safety (Fig. 2).

(3) Identify the essential elements of vaccines (antigens, adjuvants and delivery (vectors)), and while skillfully incorporating relevant basic research areas and peripheral technologies, build a platform for next-generation vaccine development research and create an optimal pathway for true clinical application (Figure 3).

The department provides an environment for a wide range of studies in molecular biology, cell biology and human clinical research, with the following items as its goals.

Contact: Ken Ishii, Division of Vaccine Science, Department of Infection and Immunology, Institute of Medical Science
1F, Research Building, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan Tell: 03-5449-5219 Fax: 03-5449-5223
e-mail: kenishii{at}
HP: Under construction (see )

Page Top